UPDATE: Wedbush Increases Fair Value Estimate on HeartWare International from $98 to $101

Wedbush maintained an Outperform rating on HeartWare International

and increased its fair value estimate from $98 to $101. Wedbush wrote, “Looking forward, we expect lumpiness in Europe to resurface to some degree, but we remain very impressed with HTWR's ability to post such strong back-to-back quarters. With regards to Q3:12, we note that the European LVAD market is typically impacted by summer seasonality, and we currently estimate HVAD implants to be down 11% as a result.” HeartWare International closed at $86.88 on Tuesday